Survival Benefit Shown With Niraparib Plus Abiraterone in BRCA+ mCRPC
Adding niraparib to abiraterone acetate and prednisone was associated with an overall survival benefit compared with AAP alone in patients with BRCA1/2-mutated metastatic castration-resistant prostate cancer.
Addition of 177Lu-PSMA-617 to Enzalutamide Improves PSA-PFS in mCRPC
Adding 177Lu-PSMA-617 to enzalutamide improved prostate-specific antigen progression-free survival in patients with metastatic castration-resistant prostate cancer.
Talazoparib Plus Enzalutamide Manageable With Dose Modification Strategy in mCRCPC
TALAPRO-2 is the first phase 3 study to evaluate talazoparib plus enzalutamide as a first-line treatment in patients with metastatic castration resistant prostate cancer.